#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
GLP-1 drugs and micronutrient risk
How GLP-1 receptor agonists and dual incretin drugs create vitamin and mineral gaps, which nutrients are most at risk, and what monitoring looks like.
Incretins after bariatric surgery
A US cohort of 208,155 post-bariatric patients: tirzepatide beat semaglutide on weight loss (17.2% vs 12.0%). No significant cardiovascular signal either way.
Bofanglutide vs semaglutide in Chinese T2D
Ann Intern Med Phase 2b: bofanglutide 18 mg biweekly cut HbA1c by 2.28 points versus 1.60 for semaglutide 1 mg weekly in Chinese patients with type 2 diabetes.
GLP-1 drugs in Medicaid: the coverage gap
Most US Medicaid programs restrict or exclude GLP-1 obesity drugs. Here is what the research says about who gets access and why coverage varies by state.
Tirzepatide and steatotic liver disease
A 2026 real-world study finds tirzepatide cut major liver complications and mortality in adults with steatotic liver disease and cardiometabolic dysfunction.
GLP-1/GIPR/FGF21 peptibody in DIO mice
A preclinical peptibody hitting GLP-1, GIPR, and FGF21 reduced body weight and improved metabolic markers in obese mice. Human translation is unknown.
How semaglutide works across the body
A 2026 review reads semaglutide through a systems medicine lens, tracing the GLP-1 receptor agonist from trial outcomes to the molecular mediators underneath.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
Mounjaro and Zepbound: same drug, different names. Here is why
Mounjaro and Zepbound are both Eli Lilly's tirzepatide. Same molecule, same doses, different brands sold for different indications. The marketing split is regulatory, not pharmacological.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.